Richard B Berry1, Matthew L Uhles2, Brian K Abaluck3, David H Winslow4, Paula K Schweitzer5, Raymond A Gaskins6, Robert C Doekel7, Helene A Emsellem8. 1. University of Florida, Gainesville, Florida. 2. Clayton Sleep Institute, Maplewood, Missouri. 3. Paoli Hospital Sleep Center, Paoli, Pennsylvania. 4. Norton Clinical Research Group, Louisville, Kentucky. 5. St. Luke's Hospital, Chesterfield, Missouri. 6. Med One Sleep, Fayetteville, North Carolina. 7. Sleep Disorders Center of Alabama, Birmingham, Alabama. 8. The Center for Sleep and Wake Disorders, Chevy Chase, Maryland.
Abstract
STUDY OBJECTIVES: Compare treatment efficacy and objective adherence between the NightBalance sleep position treatment (SPT) device and auto-adjusting positive airway pressure (APAP) in patients with exclusive positional obstructive sleep apnea (ePOSA) defined as a supine apnea-hypopnea index (sAHI) ≥ 2 times the nonsupine AHI (nsAHI) and a nsAHI < 10 events/h. METHODS: This prospective multicenter randomized crossover trial enrolled treatment naive participants with ePOSA (AHI ≥ 15 events/h and nsAHI < 10 events/h) or (AHI > 10 and < 15 events/h with daytime sleepiness and nsAH < 5 events/h). Polysomnography and objective adherence determination (device data) were performed at the end of each 6-week treatment. Patient device preference was determined at the end of the study. RESULTS: A total of 117 participants were randomized (58 SPT first, 59 APAP first). Of these, 112 started treatment with the second device (adherence cohort) and 110 completed the study (AHI cohort). The AHI on SPT was higher (mean ± standard deviation, 7.29 ± 6.8 versus 3.71 ± 5.1 events/h, P < .001). The mean AHI difference (SPT-APAP) was 3.58 events/h with a one sided 95% confidence interval upper bound of 4.96 events/h (< the prestudy noninferiority margin of 5 events/h). The average nightly adherence (all nights) was greater on SPT (345.3 ± 111.22 versus 286.98 ± 128.9 minutes, P < .0001). Participants found the SPT to be more comfortable and easier to use and 53% reported a preference for SPT assuming both devices were equally effective. CONCLUSIONS: Treatment with SPT resulted in non-inferior treatment efficacy and greater adherence compared to APAP in ePOSA suggesting that SPT is an effective treatment for this group. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea; Identifier: NCT03061071; URL: https://clinicaltrials.gov/ct2/show/NCT03061071.
RCT Entities:
STUDY OBJECTIVES: Compare treatment efficacy and objective adherence between the NightBalance sleep position treatment (SPT) device and auto-adjusting positive airway pressure (APAP) in patients with exclusive positional obstructive sleep apnea (ePOSA) defined as a supine apnea-hypopnea index (sAHI) ≥ 2 times the nonsupine AHI (nsAHI) and a nsAHI < 10 events/h. METHODS: This prospective multicenter randomized crossover trial enrolled treatment naive participants with ePOSA (AHI ≥ 15 events/h and nsAHI < 10 events/h) or (AHI > 10 and < 15 events/h with daytime sleepiness and nsAH < 5 events/h). Polysomnography and objective adherence determination (device data) were performed at the end of each 6-week treatment. Patient device preference was determined at the end of the study. RESULTS: A total of 117 participants were randomized (58 SPT first, 59 APAP first). Of these, 112 started treatment with the second device (adherence cohort) and 110 completed the study (AHI cohort). The AHI on SPT was higher (mean ± standard deviation, 7.29 ± 6.8 versus 3.71 ± 5.1 events/h, P < .001). The mean AHI difference (SPT-APAP) was 3.58 events/h with a one sided 95% confidence interval upper bound of 4.96 events/h (< the prestudy noninferiority margin of 5 events/h). The average nightly adherence (all nights) was greater on SPT (345.3 ± 111.22 versus 286.98 ± 128.9 minutes, P < .0001). Participants found the SPT to be more comfortable and easier to use and 53% reported a preference for SPT assuming both devices were equally effective. CONCLUSIONS: Treatment with SPT resulted in non-inferior treatment efficacy and greater adherence compared to APAP in ePOSA suggesting that SPT is an effective treatment for this group. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea; Identifier: NCT03061071; URL: https://clinicaltrials.gov/ct2/show/NCT03061071.
Authors: Amy M Sawyer; Nalaka S Gooneratne; Carole L Marcus; Dafna Ofer; Kathy C Richards; Terri E Weaver Journal: Sleep Med Rev Date: 2011-06-08 Impact factor: 11.609
Authors: Irene Permut; Montserrat Diaz-Abad; Wissam Chatila; Joseph Crocetti; John P Gaughan; Gilbert E D'Alonzo; Samuel L Krachman Journal: J Clin Sleep Med Date: 2010-06-15 Impact factor: 4.062
Authors: M Jeffery Mador; Thomas J Kufel; Ulysses J Magalang; S K Rajesh; Veena Watwe; Brydon J B Grant Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: James J Bignold; Georgina Deans-Costi; Mitchell R Goldsworthy; Claire A Robertson; Douglas McEvoy; Peter G Catcheside; Jeremy D Mercer Journal: J Clin Sleep Med Date: 2009-10-15 Impact factor: 4.062
Authors: Eric J Kezirian; Michael Simmons; Richard J Schwab; Peter Cistulli; Kasey K Li; Edward M Weaver; Andrew N Goldberg; Atul Malhotra Journal: Am J Respir Crit Care Med Date: 2020-12-01 Impact factor: 21.405